ReviewInflammation and regeneration2017
Clinical trials using mesenchymal stem cells in liver diseases and inflammatory bowel diseases.
Review in Inflammation and regeneration, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 79 citations in OpenAlex.
- Lyophilized mesenchymal stromal cell-derived extracellular vesicles for the oral treatment of inflammatory bowel disease: a novel cell-free therapeutic strategy.Stem cell research & therapy · 2026Article
- Mesenchymal stromal cell administration promotes macrophage-mediated bile duct regeneration.Regenerative therapy · 2026Article
- Human umbilical cord mesenchymal stem cells alleviated diarrhea-type irritable bowel syndrome by improving intestinal function.World journal of stem cells · 2025Article
- Bone marrow-derived mesenchymal stem cells reduce CClRenal failure · 2024Article
- [Successful treatment of a hepatitis B-related acute-on-chronic liver failure patient with adefovir dipivoxil combined with artificial liver and human umbilical mesenchymal stem cells].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Article
- Adipose-derived mesenchymal stem cells inhibit hepatic stellate cells activation to alleviate liver fibrosis via Hippo pathway.Stem cell research & therapy · 2024Article
- Optimization of transplantation methods using isolated mesenchymal stem/stromal cells: clinical trials of inflammatory bowel diseases as an example.Inflammation and regeneration · 2024Article
- Recent advances in pre-conditioned mesenchymal stem/stromal cell (MSCs) therapy in organ failure; a comprehensive review of preclinical studies.Stem cell research & therapy · 2023Review
- Therapeutic potential of mesenchymal stem/stromal cells (MSCs)-based cell therapy for inflammatory bowel diseases (IBD) therapy.European journal of medical research · 2023Review
- Review
- Development of Cell Therapies for Renal Disease and Regenerative Medicine.International journal of molecular sciences · 2022Review
- Stem Cell-Based Therapies for Inflammatory Bowel Disease.International journal of molecular sciences · 2022Review
- Standard toxicity study of clinical-grade allogeneic human bone marrow-derived clonal mesenchymal stromal cells.Stem cell research & therapy · 2022Article
- Application of Wharton jelly-derived mesenchymal stem cells in patients with pulmonary fibrosis.Stem cell research & therapy · 2022Review
- Stem cell therapy applied for digestive anastomosis: Current state and future perspectives.World journal of stem cells · 2022Article
- Adipose-Derived Stem Cells From Patients With Ulcerative Colitis Exhibit Impaired Immunosuppressive Function.Frontiers in cell and developmental biology · 2022Article
- Combination therapy of Juzentaihoto and mesenchymal stem cells attenuates liver damage and regresses fibrosis in mice.Regenerative therapy · 2021Article
- Synthesized HMGB1 peptide attenuates liver inflammation and suppresses fibrosis in mice.Inflammation and regeneration · 2021Article
- Transition of clinical and basic studies on liver cirrhosis treatment using cells to seek the best treatment.Inflammation and regeneration · 2021Review
- Mesenchymal Stem Cells Can Both Enhance and Inhibit the Cellular Response to DNA Immunization by Genes of Nonstructural Proteins of the Hepatitis C Virus.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesenchymal stem cell (MSC) therapies have been used in clinical trials in various fields. These cells are easily expanded, show low immunogenicity, can be acquired from medical waste, and have multiple functions, suggesting their potential applications in a variety of diseases, including liver disease and inflammatory bowel disease. MSCs help prepare the microenvironment, in response to inflammatory cytokines, by producing immunoregulatory factors that modulate the progression of inflammation by affecting dendritic cells, B cells, T cells, and macrophages. MSCs also produce a large amount of cytokines, chemokines, and growth factors, including exosomes that stimulate angiogenesis, prevent apoptosis, block oxidation reactions, promote remodeling of the extracellular matrix, and induce differentiation of tissue stem cells. According to ClinicalTrials.gov, more than 680 clinical trials using MSCs are registered for cell therapy of many fields including liver diseases (more than 40 trials) and inflammatory bowel diseases (more than 20 trials). In this report, we introduce background and clinical studies of MSCs in liver disease and inflammatory bowel diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.